Clinical Trials Logo

Clinical Trial Summary

The investigators recently showed an abnormal expansion of NK-like CD4+ T cells in Wegener's granulomatosis (WG), mainly in the diffuse vasculitis presentation. These cells expressed an assortment of activating NK cell receptors and their signaling partners, in particular DAP12. The investigators hypothesize that DAP12, or a downstream signaling target of DAP12, is the missing link between the different cell components involved in WG (neutrophils, macrophages, CD4 T cells).


Clinical Trial Description

The investigators will test our hypothesis of "DAP-12 gain-of-function" by quantitative (mRNA and protein) and qualitative (DNA, signaling and cellular activation) analysis of the DAP12 signaling pathway in WG patients with localized (group 1; n=30) or diffuse WG (group 2; n=30) by comparison with patients with micro polyangitis (group 3; n=30), or with sarcoidosis ( group 4; n=30), and healthy blood donors (group 5; n=30). Blood samples will be collected during a routine medical visit. These results may help to design future therapeutic strategies based on modulation of specific intra-cellular pathways involved in the disease. ;


Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label


Related Conditions & MeSH terms


NCT number NCT01167491
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact
Status Completed
Phase N/A
Start date May 2010
Completion date September 2014

See also
  Status Clinical Trial Phase
Terminated NCT00747461 - Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD") Phase 4
Completed NCT00072592 - An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies Phase 1
Recruiting NCT02593565 - Vasculitis Pregnancy Registry
Completed NCT00307593 - RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides N/A
Active, not recruiting NCT00006055 - Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases N/A
Completed NCT00001473 - Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides N/A
Terminated NCT01408836 - Plasma Exchange for Renal Vasculitis Phase 2/Phase 3
Completed NCT00001256 - Steroids and Methotrexate to Treat Systemic Vasculitis Phase 2
Completed NCT00040248 - Daclizumab to Treat Wegener's Granulomatosis Phase 2
Completed NCT00005007 - Etanercept for Wegener's Granulomatosis Phase 2/Phase 3
Completed NCT00307671 - Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Phase 4
Completed NCT01988506 - Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases Phase 2
Recruiting NCT01066208 - American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis N/A
Completed NCT00104299 - Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis Phase 2/Phase 3
Completed NCT00753103 - Anti-Cytokine Therapy for Vasculitis Phase 2
Completed NCT02176070 - Reproductive Health in Men and Women With Vasculitis N/A
Completed NCT00468208 - Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis Phase 1/Phase 2
Completed NCT00004567 - Comparison of Treatments to Maintain Disease Remission in Patients With Wegener's Granulomatosis and Related Vasculitis Syndromes Phase 2
Completed NCT00001901 - Etanercept to Treat Wegener's Granulomatosis Phase 2
Completed NCT00430105 - Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides Phase 2/Phase 3